Participants in this round included Prateek Maheshwari, Pradip Todi via O2 Angels, and the tal64 syndicate. While the current funding round is primarily based on Janitri’s proven B2B success, a portion of the raised funds will be strategically allocated to enter the consumer segment.
Kacholia said in a statement, “Arun has spent time and effort in understanding unmet customer needs in the 1000-days journey of maternal care. Janitri’s product is compact, full function, and enables cost-effective monitoring of mother and newborn for both hospital and home segment. It is a large market in India and overseas and hopefully, Janitri will identify more such market gaps to build a large and profitable medtech company out of India.”
Agarwal said in a statement, “Janitri is building products focused on the 1000-day pregnancy journey of a mother and child. The goal is to bring joy to the mother, father, and the whole family as they anticipate and prepare for the arrival of their newborn into the world.”
With this new funding, Janitri plans to expand its sales and support network across India; enhance its product suite with new offerings focused on in-home maternal healthcare; develop wearable vital signs patches for remote monitoring in the third trimester; create neonatal monitoring solutions for high-risk newborns and scale operations to reach Rs 3 crore monthly revenue in the next 12 months.
The company’s flagship product, Keyar, is an intrapartum monitoring device that tracks vital signs of pregnant women during labor, helping detect complications early and enabling timely interventions. Janitri addresses a critical gap in healthcare delivery — inadequate vital signs monitoring during labor, which contributes significantly to maternal and child mortality rates.
